We here demonstrate that immune-cell intrinsic PKCθ activity plays a crucial role in the progression of muscular dystrophy, and targeting PKCθ can be proposed as a valuable therapeutic strategy for the disease. Here, PRRT2 is linked to muscular dystrophy.